Pheochromocytoma and paraganglioma pathogenesis: Learning from genetic heterogeneity

Nature Reviews Cancer

Volumn 14, Issue 2, 2014, Pages 108-119

  Dahia, Patricia L M ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENETIC HETEROGENEITY; HUMANS; MUTATION; PARAGANGLIOMA; PHEOCHROMOCYTOMA;

EID: 84894556457     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3648     Document Type: Review

References (159)

1. Lenders, J. W., Eisenhofer, G., Mannelli, M. & Pacak, K. Phaeochromocytoma. Lancet 366, 665-675 (2005).
2. Manger, W. M. An overview of pheochromocytoma: history, current concepts, vagaries, and diagnostic challenges. Ann. NY Acad. Sci. 1073, 1-20 (2006).
3. Welander, J., Soderkvist, P. & Gimm, O. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr. Relat. Cancer 18, R253-R276 (2011).
4. Jimenez, C. et al. Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Curr. Oncol. Rep. 15, 356-371 (2013).
5. Gimenez-Roqueplo, A. P., Dahia, P. L. & Robledo, M. An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm. Metab. Res. 44, 328-333 (2012).
6. Neumann, H. P. et al. Germ-line mutations in nonsyndromic pheochromocytoma. N. Engl. J. Med. 346, 1459-1466 (2002).
7. Burnichon, N. et al. Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Hum. Mol. Genet. 21, 5397-5405 (2012).
8. Burnichon, N. et al. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin. Cancer Res. 18, 2828-2837 (2012).
9. Welander, J. et al. Integrative genomics reveals frequent somatic NF1 mutations in sporadic pheochromocytomas. Hum. Mol. Genet. 21, 5406-5416 (2012).
10. Toledo, R. A. et al. In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas. Endocr. Relat. Cancer 20, 349-359 (2013).
11. Dahia, P. L. et al. A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet. 1, 72-80 (2005).
12. Burnichon, N. et al. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum. Mol. Genet. 20, 3974-3985 (2011).
13. Baysal, B. E. et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287, 848-851 (2000).
14. Zbuk, K. M. & Eng, C. Cancer phenomics: RET and PTEN as illustrative models. Nature Rev. Cancer 7, 35-45 (2007).
15. Kouvaraki, M. A. et al. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15, 531-544 (2005).
16. Kloos, R. T. et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19, 565-612 (2009).
17. Comino-Mendez, I. et al. Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. Hum. Mol. Genet. 22, 2169-2176 (2013).
18. Favier, J., Buffet, A. & Gimenez-Roqueplo, A. P. HIF2A mutations in paraganglioma with polycythemia. N. Engl J. Med. 367, 2161-2162 (2012).
19. Maher, E. R. HIF2 and endocrine neoplasia: an evolving story. Endocr. Relat. Cancer 20, C5-C7 (2013).
20. Zhuang, Z. et al. Somatic HIF2A gain?of?function mutations in paraganglioma with polycythemia. N. Engl. J. Med. 367, 922-930 (2012).
21. Fishbein, L., Merrill, S., Fraker, D. L., Cohen, D. L. & Nathanson, K. L. Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing. Ann. Surg. Oncol. 20, 1444-1450 (2013).
22. Jafri, M. & Maher, E. R. The genetics of phaeochromocytoma: using clinical features to guide genetic testing. Eur. J. Endocrinol. 166, 151-158 (2012).
23. Buffet, A. et al. A decade of genetic testing for pheochromocytoma and paraganglioma. Horm. Metab. Res. 44, 359-366 (2012).
24. Eisenhofer, G. et al. Distinct gene expression profiles in norepinephrine-and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocr. Relat. Cancer 11, 897-911 (2004).
25. Lopez-Jimenez, E. et al. Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol. Endocrinol. 24, 2382-2391 (2010).
26. Semenza, G. L. HIF?1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 107, 1-3 (2001).
27. Gruber, M. & Simon, M. C. Hypoxia-inducible factors, hypoxia, and tumor angiogenesis. Curr. Opin. Hematol. 13, 169-174 (2006).
28. Ivan, M. et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292, 464-468 (2001).
29. Jaakkola, P. et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2?regulated prolyl hydroxylation. Science 292, 468-472 (2001).
30. Kaelin, W. G. Jr The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nature Rev. Cancer 8, 865-873 (2008).
31. Stebbins, C. E., Kaelin, W. G. Jr & Pavletich, N. P. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 284, 455-461 (1999).
32. Kim, W. Y. & Kaelin, W. G. Role of VHL gene mutation in human cancer. J. Clin. Oncol. 22, 4991-5004 (2004).
33. Shen, C. & Kaelin, W. G. Jr. The VHL/HIF axis in clear cell renal carcinoma. Semin. Cancer Biol. (2012).
34. Raval, R. R. et al. Contrasting properties of hypoxiainducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell. Biol. 25, 5675-5686 (2005).
35. Keith, B., Johnson, R. S. & Simon, M. C. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nature Rev. Cancer 12, 9-22 (2012).
36. Gordan, J. D., Bertout, J. A., Hu, C. J., Diehl, J. A. & Simon, M. C. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 11, 335-347 (2007).
37. Dang, C. V., Kim, J. W., Gao, P. & Yustein, J. The interplay between MYC and HIF in cancer. Nature Rev. Cancer 8, 51-56 (2008).
38. Kondo, K., Klco, J., Nakamura, E., Lechpammer, M. & Kaelin, W. G. Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1, 237-246 (2002).
39. Kondo, K., Kim, W. Y., Lechpammer, M. & Kaelin, W. G. Jr. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1, E83 (2003). Papers 36, 38 and 39 propose oncogenic roles for HIF2a.
40. Rechsteiner, M. P. et al. VHL gene mutations and their effects on hypoxia inducible factor HIFa: identification of potential driver and passenger mutations. Cancer Res. 71, 5500-5511 (2011).
41. Pollard, P. J. et al. Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations. J. Clin. Endocrinol. Metab. 91, 4593-4598 (2006).
42. Favier, J. et al. The Warburg effect is genetically determined in inherited pheochromocytomas. PLoS ONE 4, e7094 (2009).
43. Shen, C. et al. Genetic and functional studies implicate HIF1alpha as a 14q kidney cancer suppressor gene. Cancer Discov. 1, 222-235 (2011).
44. Luo, W., Chang, R., Zhong, J., Pandey, A. & Semenza, G. L. Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression. Proc. Natl Acad. Sci. 109, E3367-E3376 (2012).
45. Clifford, S. C. et al. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum. Mol. Genet. 10, 1029-1038 (2001).
46. Hoffman, M. A. et al. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum. Mol. Genet. 10, 1019-1027 (2001).
47. Barontini, M. & Dahia, P. L. VHL disease. Best Pract. Res. Clin. Endocrinol. Metab. 24, 401-413 (2010).
48. Kaelin, W. G. Jr Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. Cancer 115, 2262-2272 (2009).
49. Li, M. & Kim, W. Y. Two sides to every story: the HIFdependent and HIF-independent functions of pVHL. J. Cell. Mol. Med. 15, 187-195 (2010).
50. Cecchini, G. Respiratory complex II: Role in cellular physiology and disease. Biochim. Biophys. Acta (BBA)-Bioenerg. 1827, 541-542 (2013).
51. Astuti, D. et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am. J. Hum. Genet. 69, 49-54 (2001).
52. Burnichon, N. et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum. Mol. Genet. 19, 3011-3020 (2010).
53. Niemann, S. & Muller, U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nature Genet. 26, 268-270 (2000).
54. Hao, H. X. et al. SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science 325, 1139-1142 (2009).
55. Vanharanta, S. et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHBassociated heritable paraganglioma. Am. J. Hum. Genet. 74, 153-159 (2004).
56. Janeway, K. A. et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc. Natl Acad. Sci. USA 108, 314-318 (2011).
57. Papathomas, T. et al. Non-pheochromocytoma/paraganglioma tumors in patients with succinate dehydrogenase-related pheochromocytomaparaganglioma syndromes: a clinicopathologic and molecular analysis. Eur. J. Endocrinol. 170, 1-12 (2013).
58. Selak, M. A. et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7, 77-85 (2005).
59. Xiao, M. et al. Inhibition of alpha-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 26, 1326-1338 (2012).
60. Letouze, E. et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell 23, 739-752 (2013).
61. Killian, J. K. et al. Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov. 3, 648-657 (2013).
62. Fendt, S. M. et al. Reductive glutamine metabolism is a function of the alpha-ketoglutarate to citrate ratio in cells. Nature Commun. 4, 2236 (2013).
63. He, W. et al. Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature 429, 188-193 (2004).
64. Hakak, Y. et al. The role of the GPR91 ligand succinate in hematopoiesis. J. Leukoc. Biol. 85, 837-843 (2009).
65. Sapieha, P. et al. The succinate receptor GPR91 in neurons has a major role in retinal angiogenesis. Nature Med. 14, 1067-1076 (2008).
66. Tomlinson, I. P. et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nature Genet. 30, 406-410 (2002).
67. Isaacs, J. S. et al. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability. Cancer Cell 8, 143-153 (2005).
68. Sullivan, L. B. et al. The Proto-oncometabolite Fumarate Binds Glutathione to Amplify ROSDependent Signaling. Mol. Cell 51, 236-248 (2013).
69. Sudarshan, S. et al. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxiainducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol. Cell. Biol. 29, 4080-4090 (2009).
70. Smith, E. H., Janknecht, R. & Maher, L. J. 3rd. Succinate inhibition of a-ketoglutarate-dependent enzymes in a yeast model of paraganglioma. Hum. Mol. Genet. 16, 3136-3148 (2007).
71. Ishii, T. et al. A mutation in the SDHC gene of complex II increases oxidative stress, resulting in apoptosis and tumorigenesis. Cancer Res. 65, 203-209 (2005).
72. Selak, M. A., Duran, R. V. & Gottlieb, E. Redox stress is not essential for the pseudo-hypoxic phenotype of succinate dehydrogenase deficient cells. Biochim. Biophys. Acta 1757, 567-572 (2006).
73. Guzy, R. D., Sharma, B., Bell, E., Chandel, N. S. & Schumacker, P. T. Loss of the SdhB, but Not the SdhA, subunit of complex II triggers reactive oxygen speciesdependent hypoxia-inducible factor activation and tumorigenesis. Mol. Cell. Biol. 28, 718-731 (2008).
74. Pollard, P. J. et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum. Mol. Genet. 14, 2231-2239 (2005).
75. Taieb, D. et al. First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A-related polycythemia-paraganglioma syndrome. J. Clin. Endocrinol. Metab. 98, E908-E913 (2013).
76. Lorenzo, F. R. et al. A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. J. Mol. Med. (Berl.) 91, 507-512 (2013).
77. McDonough, M. A. et al. Cellular oxygen sensing: Crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2). Proc. Natl Acad. Sci. USA 103, 9814-9819 (2006).
78. Min, J. H. et al. Structure of an HIF-1alpha-pVHL complex: hydroxyproline recognition in signaling. Science 296, 1886-1889 (2002).
79. Dahia, P. L. The genetic landscape of pheochromocytomas and paragangliomas: somatic mutations take center stage. J. Clin. Endocrinol. Metab. 98, 2679-2681 (2013).
80. Pacak, K. et al. New syndrome of paraganglioma and somatostatinoma associated with polycythemia. J. Clin. Oncol. 31, 1690-1698 (2013).
81. Percy, M. J. et al. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N. Engl. J. Med. 358, 162-168 (2008).
82. Tian, H., Hammer, R. E., Matsumoto, A. M., Russell, D. W. & McKnight, S. L. The hypoxiaresponsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev. 12, 3320-3324 (1998).
83. Nilsson, H. et al. HIF-2alpha expression in human fetal paraganglia and neuroblastoma: relation to sympathetic differentiation, glucose deficiency, and hypoxia. Exp. Cell Res. 303, 447-456 (2005).
84. Ladroue, C. et al. PHD2 mutation and congenital erythrocytosis with paraganglioma. N. Engl. J. Med. 359, 2685-2692 (2008).
85. Astuti, D. et al. Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility. Endocr. Relat. Cancer 18, 73-83 (2011).
86. Gaal, J. et al. Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. J. Clin. Endocrinol. Metab. 95, 1274-1278 (2010).
87. Yao, L. et al. Mutations of the metabolic genes IDH1, IDH2, and SDHAF2 are not major determinants of the pseudohypoxic phenotype of sporadic pheochromocytomas and paragangliomas. J. Clin. Endocrinol. Metab. 95, 1469-1472 (2010).
88. Mulligan, L. M. et al. Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363, 458-460 (1993).
89. Schuchardt, A., D'Agati, V., Larsson-Blomberg, L., Costantini, F. & Pachnis, V. The c-ret receptor tyrosine kinase gene is required for the development of the kidney and enteric nervous system. Nature 367, 380-383 (1994).
90. Jing, S. et al. GDNF-induced activation of the Ret protein tyrosine kinase is mediated by GDNFR-a, a novel receptor for GDNF. Cell 85, 1113-1124 (1996).
91. Neumann, H. P. et al. Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II. JAMA 274, 1149-1151 (1995).
92. Milos, I. N. et al. Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC>TGG) mutation. Endocr. Relat. Cancer 15, 1035-1041 (2008).
93. Waguespack, S. G., Rich, T. A., Perrier, N. D., Jimenez, C. & Cote, G. J. Management of medullary thyroid carcinoma and MEN2 syndromes in childhood. Nature Rev. Endocrinol. 7, 596-607 (2011).
94. Toledo, S. P., dos Santos, M. A., Toledo Rde, A. & Lourenco, D. M. Jr. Impact of RET proto-oncogene analysis on the clinical management of multiple endocrine neoplasia type 2. Clin. (Sao Paulo) 61, 59-70 (2006).
95. Wells, S. A. Jr et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind Phase III trial. J. Clin. Oncol. 30, 134-141 (2012).
96. Asai, N., Iwashita, T., Matsuyama, M. & Takahashi, M. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol. Cell. Biol. 3, 1613-1619 (1995).
97. Santoro, M. et al. Activation of RET as a dominant transforming gene by germline mutations of MEN 2A and MEN 2B. Science 267, 381-383 (1995).
98. Smith-Hicks, C. L., Sizer, K. C., Powers, J. F., Tischler, A. S. & Costantini, F. C-cell hyperplasia, pheochromocytoma and sympathoadrenal malformation in a mouse model of multiple endocrine neoplasia type 2B. EMBO J. 19, 612-622 (2000).
99. Richardson, D. S., Lai, A. Z. & Mulligan, L. M. RET ligand-induced internalization and its consequences for downstream signaling. Oncogene 25, 3206-3211 (2006).
100. Glerup, S. et al. SorLA controls neurotrophic activity by sorting of GDNF and its receptors GFRalpha1 and RET. Cell Rep. 3, 186-199 (2013).
101. Hyndman, B. D., Gujral, T. S., Krieger, J. R., Cockburn, J. G. & Mulligan, L. M. Multiple Functional Effects of RET Kinase Domain Sequence Variants in Hirschsprung Disease. Hum. Mutat. 34, 132-142 (2013).
102. Thosani, S. et al. The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2. J. Clin. Endocrinol. Metab. 98, E1813-E1819 (2013).
103. Ferner, R. E. Neurofibromatosis 1. Eur. J. Hum. Genet. 15, 131-138 (2007).
104. North, K. Neurofibromatosis type 1. Am. J. Med. Genet. 97, 119-127 (2000).
105. Viskochil, D. et al. Deletions and translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 62, 187-192 (1990).
106. Ballester, R. et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 63, 851-859 (1990).
107. Basu, T. N. et al. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 356, 713-715 (1992).
108. Cichowski, K., Santiago, S., Jardim, M., Johnson, B. W. & Jacks, T. Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor. Genes Dev. 17, 449-454 (2003).
109. Powers, J. F., Evinger, M. J., Zhi, J., Picard, K. L. & Tischler, A. S. Pheochromocytomas in Nf1 knockout mice express a neural progenitor gene expression profile. Neuroscience 147, 928-937 (2007).
110. Johannessen, C. M. et al. TORC1 is essential for NF1-associated malignancies. Curr. Biol. 18, 56-62 (2008).
111. Qin, Y. et al. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nature Genet. 42, 229-233 (2010).
112. Comino-Mendez, I. et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nature Genet. 43, 663-667 (2011). Papers 111 and 112 report novel classes of pheochromocytoma susceptibility genes.
113. Blackwood, E. M., Lüscher, B. & Eisenman, R. N. Myc and Max associate in vivo. Genes Dev. 6, 71-80 (1992).
114. Cascon, A. & Robledo, M. MAX and MYC: a heritable breakup. Cancer Res. 72, 3119-3124 (2012).
115. Ribon, V., Leff, T. & Saltiel, A. R. c-Myc does not require max for transcriptional activity in PC-12 cells. Mol. Cell Neurosci. 5, 277-282 (1994).
116. Seeger, R. C. et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N. Engl. J. Med. 313, 1111-1116 (1985).
117. Pourdehnad, M. et al. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc. Natl Acad. Sci. 110, 11988-11993 (2013).
118. Bernstein, B. E. et al. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57-74 (2012).
119. Burnichon, N. et al. A novel TMEM127 mutation in a patient with familial bilateral pheochromocytoma. Eur. J. Endocrinol. 164, 141-145 (2011).
120. Takeichi, N. et al. Identical germline mutations in the TMEM127 gene in two unrelated Japanese patients with bilateral pheochromocytoma. Clin. Endocrinol. (Oxf.) 77, 707-714 (2012).
121. Elston, M. S., Meyer-Rochow, G. Y., Prosser, D., Love, D. R. & Conaglen, J. V. Novel mutation in the TMEM127 gene associated with phaeochromocytoma. Intern. Med. J. 43, 449-451 (2013).
122. Abermil, N. et al. TMEM127 screening in a large cohort of patients with pheochromocytoma and/or paraganglioma. J. Clin. Endocrinol. Metab. 97, E805-809 (2012).
123. Neumann, H. P. et al. Germline mutations of the TMEM127 gene in patients with paraganglioma of head and neck and extraadrenal abdominal sites. J. Clin. Endocrinol. Metab. 96, E1279-1282 (2011).
124. Yao, L. et al. Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. JAMA 304, 2611-2619 (2010).
125. Qin, Y. et al. The tumor susceptibility gene TMEM127 is mutated in renal cell carcinomas and modulates endolysosomal function. Hum. Mol. Genet. http://dx.doi.org/10.1093/hmg/ddt638 (2013).
126. Parachoniak, C. A. & Park, M. Dynamics of receptor trafficking in tumorigenicity. Trends Cell Biol. 22, 231-240 (2012).
127. Wang, Y. et al. Regulation of endocytosis via the oxygen-sensing pathway. Nature Med. 15, 319-324 (2009).
128. Wang, Y. et al. Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factor-mediated upregulation of caveolin-1. Proc. Natl Acad. Sci. 109, 4892-4897 (2012).
129. Brugarolas, J. & Kaelin, W. G. Jr. Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell 6, 7-10 (2004).
130. Gordan, J. D. et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14, 435-446 (2008).
131. Duvel, K. et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 39, 171-183 (2010).
132. Semenza, G. L. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J. Appl. Physiol. 88, 1474-1480 (2000).
133. Lamming, D. W. & Sabatini, D. M. A central role for mTOR in lipid homeostasis. Cell Metab. 18, 465-469 (2013).
134. Lee, S. et al. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: Developmental culling and cancer. Cancer Cell 8, 155-167 (2005).
135. Crona, J. et al. Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing. J. Clin. Endocrinol. Metab. 98, E1266-E1271 (2013).
136. Dahia, P. L. et al. Novel pheochromocytoma susceptibility loci identified by integrative genomics. Cancer Res. 65, 9651-9658 (2005).
137. Huang, F. W. et al. Highly recurrent TERT promoter mutations in human melanoma. Science 339, 957-959 (2013).
138. Nolting, S. et al. Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines. J. Mol. Endocrinol. 49, 79-96 (2012).
139. Ayala-Ramirez, M. et al. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas. J. Clin. Endocrinol. Metab. 97, 4040-4050 (2012).
140. Oh, D. Y. et al. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas. Cancer 118, 6162-6170 (2012).
141. Hescot, S. et al. One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. J. Clin. Endocrinol. Metab. 98, 4006-4012 (2013).
142. Gimenez-Roqueplo, A. P. et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res. 63, 5615-5621 (2003).
143. Loriot, C. et al. Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations. J. Clin. Endocrinol. Metab. 97, E954-E962 (2012).
144. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
145. Tischler, A. S., DeLellis, R. A., Nunnemacher, G. & Wolfe, H. J. Acute stimulation of chromaffin cell proliferation in the adult rat adrenal medulla. Lab Invest. 58, 733-735 (1988).
146. Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033 (2009).
147. Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L. & Denko, N. C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell. Metab. 3, 187-197 (2006).
148. Kim, J. W., Tchernyshyov, I., Semenza, G. L. & Dang, C. V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell. Metab. 3, 177-185 (2006).
149. DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G. & Thompson, C. B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell. Metab. 7, 11-20 (2008).
150. Schlisio, S. et al. The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev. 22, 884-893 (2008).
151. Yeh, I. T. et al. A germline mutation of the KIF1B beta gene on 1p36 in a family with neural and nonneural tumors. Hum. Genet. 124, 279-285 (2008).
152. Yoshimoto, K. et al. ras mutations in endocrine tumors: mutation detection by polymerase chain reaction-single strand conformation polymorphism. Jpn J. Cancer Res. 83, 1057-1062 (1992)
153. Forbes, S. A. et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945-D950 (2011).
154. Wadt, K. et al. A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma. Pigment Cell. Melanoma Res. 25, 815-818 (2012).
155. Hensen, E. F. et al. Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families. Oncogene 23, 4076-4083 (2004).
156. Baysal, B. E. Mitochondrial complex II and genomic imprinting in inheritance of paraganglioma tumors. Biochim. Biophys. Acta (BBA)-Bioenerg. 1827, 573-577 (2013).
157. Biesecker, L. G. & Spinner, N. B. A genomic view of mosaicism and human disease. Nature Rev. Genet. 14, 307-320 (2013).
158. Cantor, A. M., Rigby, C. C., Beck, P. R. & Mangion, D. Neurofibromatosis, phaeochromocytoma, and somatostatinoma. Br. Med. J. (Clin. Res. Ed) 285, 1618-1619 (1982).
159. Buffet, A. et al. Mosaicism in HIF2A-related polycythaemia-paraganglioma syndrome. J. Clin. Endocrinol. Metab. http://dx.doi.org/10.1210/jc.2013-2600